{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroectodermal+Tumors&page=16", "query": { "condition": "Neuroectodermal Tumors", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 5014, "total_pages": 502, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroectodermal+Tumors&page=17&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroectodermal+Tumors&page=15&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T08:17:24.227Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00003996", "title": "Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "carmustine", "type": "DRUG" }, { "name": "chemotherapy", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 93, "start_date": "1999-05", "completion_date": "2008-05", "has_results": false, "last_update_posted_date": "2016-12-07", "last_synced_at": "2026-10-27T08:17:24.227Z", "location_count": 19, "location_summary": "Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 16 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Cedar Rapids", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003996" }, { "nct_id": "NCT01702896", "title": "Interleukin-2 in Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma Metastatic" ], "interventions": [ { "name": "Interleukin-2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Western Regional Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2012-09", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2018-04-05", "last_synced_at": "2026-10-27T08:17:24.227Z", "location_count": 1, "location_summary": "Goodyear, Arizona", "locations": [ { "city": "Goodyear", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01702896" }, { "nct_id": "NCT06517888", "title": "Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Vestibular Schwannoma" ], "interventions": [ { "name": "AAVAnc80-antiVEGF via Akouos Delivery Device", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Akouos, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2025-01-17", "completion_date": "2029-08", "has_results": false, "last_update_posted_date": "2026-04-06", "last_synced_at": "2026-10-27T08:17:24.227Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Rochester, Minnesota • Nashville, Tennessee + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06517888" }, { "nct_id": "NCT00238303", "title": "Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma", "Recurrent Adult Brain Tumor" ], "interventions": [ { "name": "vorinostat", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 103, "start_date": "2005-09", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2014-05-23", "last_synced_at": "2026-10-27T08:17:24.227Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00238303" }, { "nct_id": "NCT01941927", "title": "Trametinib With GSK2141795 in BRAF Wild-type Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Trametinib (GSK1120212)", "type": "DRUG" }, { "name": "GSK2141795", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adil Daud", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2013-09-10", "completion_date": "2017-05-03", "has_results": true, "last_update_posted_date": "2020-02-12", "last_synced_at": "2026-10-27T08:17:24.227Z", "location_count": 2, "location_summary": "San Francisco, California • New York, New York", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01941927" }, { "nct_id": "NCT02632370", "title": "5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Malignant Gliomas" ], "interventions": [ { "name": "Gliolan®", "type": "DRUG" }, { "name": "Fluorescence-Guided Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Constantinos Hadjipanayis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 69, "start_date": "2016-05", "completion_date": "2018-12-31", "has_results": false, "last_update_posted_date": "2019-02-25", "last_synced_at": "2026-10-27T08:17:24.227Z", "location_count": 17, "location_summary": "Washington D.C., District of Columbia • Delray Beach, Florida • Atlanta, Georgia + 13 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Delray Beach", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boise", "state": "Idaho" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02632370" }, { "nct_id": "NCT05535166", "title": "Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Medulloblastoma" ], "interventions": [ { "name": "Surgical resection", "type": "PROCEDURE" }, { "name": "Ommaya/VPS", "type": "PROCEDURE" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Irradiation", "type": "RADIATION" }, { "name": "Educational and Media Intervention", "type": "OTHER" }, { "name": "SOC, Educational and Media Intervention", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION", "OTHER" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "59 Months", "sex": "ALL", "summary": "Up to 59 Months" }, "enrollment_count": 130, "start_date": "2022-12-20", "completion_date": "2035-07", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-27T08:17:24.227Z", "location_count": 10, "location_summary": "Palo Alto, California • Orlando, Florida • Tampa, Florida + 7 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05535166" }, { "nct_id": "NCT00562380", "title": "AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Prostate Cancer", "Sarcoma", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "ganitumab", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "PROCEDURE" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2005-10", "completion_date": "2010-06", "has_results": false, "last_update_posted_date": "2013-07-18", "last_synced_at": "2026-10-27T08:17:24.227Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00562380" }, { "nct_id": "NCT04987996", "title": "GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "GR-MD-02", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Providence Health & Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2023-07-01", "completion_date": "2031-07-01", "has_results": false, "last_update_posted_date": "2023-06-06", "last_synced_at": "2026-10-27T08:17:24.227Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04987996" }, { "nct_id": "NCT01435369", "title": "Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Malignant Melanoma" ], "interventions": [ { "name": "CT-011", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medivation, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 103, "start_date": "2011-11", "completion_date": "2013-08", "has_results": false, "last_update_posted_date": "2016-01-21", "last_synced_at": "2026-10-27T08:17:24.227Z", "location_count": 16, "location_summary": "New Haven, Connecticut • Tampa, Florida • Chicago, Illinois + 9 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01435369" } ] }